NCT04561258View on ClinicalTrials.gov

Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

August 15, 2022

Study Completion Date

November 21, 2022

Conditions
HIV
Interventions
BIOLOGICAL

AGT103-T

An autologous, genetically modified PBMC product enriched with HIV-specific and resistant CD4 T cells

Trial Locations (2)

20007

Georgetown University, Washington D.C.

20017

Washington Health Institute, Washington D.C.

Sponsors
All Listed Sponsors
lead

American Gene Technologies International Inc.

INDUSTRY

NCT04561258 - Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy | Biotech Hunter | Biotech Hunter